Researchers Mapped New mRNA Delivery Routes

Scientists in Atlanta demonstrated that GI tract delivery of nanoparticles reduces unintended organ toxicity.

Updated on Oct. 5, 2026 in Diabetes

A close-up of a laboratory pipette tip suspended over a small vial containing a glowing nanoparticle sample. — Researchers at the Georgia Institute of Technology and Emory University demonstrated that GI tract delivery of mRNA nanoparticles significantly reduces toxicity in non-target organs. AI Illustration. Upload story photo >

Live Poll

Would you prefer an oral or GI-based method over a traditional needle injection for your vaccines?

Researchers at Georgia Institute of Technology and Emory University identified that delivering mRNA lipid nanoparticles through the gastrointestinal tract alters systemic distribution in mice. Published in September 2026, the study found this method reduced drug accumulation in the liver, lungs, and spleen.

Why it matters

Traditional mRNA delivery often causes unintended interactions with non-target organs, creating toxicity risks. By remapping delivery routes to the GI tract, researchers aim to increase the precision of therapeutic treatments while improving overall safety.

The study utilized microneedle injections to target specific regions of the gastrointestinal tract in mouse models. This research was supported by the National Institutes of Health under grant identification number R35GM150689.

The players

Georgia Institute of Technology

This is a public research university in Atlanta that specializes in technology-focused education and scientific innovation.

Emory University

This is a private research university located in Atlanta known for its extensive medical and health sciences programs.

The details

The research team mapped nanoparticle travel patterns to determine how delivery location affects systemic distribution. By targeting the stomach to reach the pancreas, researchers successfully improved blood sugar regulation in diabetic mouse models.

The research findings were published in the journal ACS Nano in September 2026.
The official notification of the research occurred on October 5, 2026.

The Big Picture

This study follows the National Institutes of Health R35GM150689 grant program, which supports foundational investigations into novel drug delivery mechanisms. The work marks a shift from systemic administration toward site-specific delivery paradigms in gene therapy.

This discovery could lead to more effective treatments for chronic conditions like diabetes by improving how medicine is processed in the body. Future applications may reduce the side effects currently associated with systemic mRNA therapies.

The takeaway

This research provides a proof-of-concept for avoiding liver and lung toxicity during mRNA therapy. These findings suggest that future treatments may prioritize targeted GI delivery to optimize patient outcomes.